# US 2024/0201164 A1 · Evaluation of patients with cystic fibrosis using sweat

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201164 A1
- Document ID: US20240201164A1
- Status: Published application
- Kind: A1
- Application number: 18/288,008
- Filed: 2022-04-21
- Published: 2024-06-20
- Earliest claimed: 2021-04-22
- Assignees: Research Institute At Nationwide Children's Hospital
- Applicants: The Research Institute At Nationwide Children's Hospital
- Inventors: Don Hayes; Fred Woodley; Ben Kopp
- Web page: https://patentgrep.com/patent/US20240201164A1

## CPC

- A61P 11/12: Mucolytics
- G01N 33/487: of liquid biological material
- G01N 30/88: Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 2030/027: {Liquid chromatography}
- G01N 2030/884: {organic compounds}
- G01N 2800/12: Pulmonary diseases
- G01N 2800/382: Cystic fibrosis
- G01N 2800/50: Determining the risk of developing a disease
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of determining if a patient having cystic fibrosis has an increased risk of having or developing pulmonary exacerbations is described. The method includes determining the level of one or more metabolites associated with pulmonary exacerbations in a sweat sample from the patient, and characterizing the patient as having an increased risk of having or developing pulmonary exacerbations if one or more metabolites associated with pulmonary exacerbation are significantly different from a control value. A method of evaluating the response of a patient having pulmonary exacerbations to treatment is also described.

## Claims

### Claim 1

A method of determining if a patient having cystic fibrosis has an increased risk of having or developing pulmonary exacerbations, comprising:
determining the level of one or more metabolites associated with pulmonary exacerbations in a sweat sample from the patient, and
characterizing the patient as having an increased risk of having or developing pulmonary exacerbations if the level of one or more metabolites associated with pulmonary exacerbation are significantly different from a control value.

### Claim 2 (depends on 1)

The method of claim 1, further comprising the step of obtaining a sweat sample from the patient.

### Claim 3 (depends on 2)

The method of claim 2, wherein the sweat sample is obtained using a skin patch.

### Claim 4 (depends on 1)

The method of claim 1, wherein the level of the one or more metabolites is determined using high performance liquid chromatography.

### Claim 5 (depends on 1)

The method of claim 1, wherein the metabolites associated with pulmonary exacerbations are selected from the group consisting of thymidine, N-acetyl tyrosine, 2-piperidinone, and adipate C6-DC.

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more metabolites associated with pulmonary exacerbations comprises thymidine.

### Claim 7

A method of evaluating the response of a patient with cystic fibrosis having pulmonary exacerbations to treatment, comprising:
determining the level of one or more metabolites associated with pulmonary exacerbations in a sweat sample from the patient;
comparing the level of one or more metabolites associated with pulmonary exacerbations to a control value, and
characterizing the patient as responding well to treatment if the level of one or more metabolites associated with pulmonary exacerbations has a value closer to the control value.

### Claim 8 (depends on 7)

The method of claim 7, further comprising the step of obtaining a sweat sample from the patient.

### Claim 9 (depends on 8)

The method of claim 8, wherein the sweat sample is obtained using a skin patch.

### Claim 10 (depends on 7)

The method of claim 7, wherein the one or more metabolites are determined using high performance liquid chromatography.

### Claim 11 (depends on 7)

The method of claim 7, wherein the metabolites associated with pulmonary exacerbations comprise thymidine, N-acetyl tyrosine, 2-piperidinone, and adipate C6-DC.

### Claim 12 (depends on 7)

The method of claim 7, wherein the one or more metabolites associated with pulmonary exacerbations comprise thymidine.

### Claim 13 (depends on 6)

The method of claim 6, wherein the treatment is antibiotic treatment.
